Angel E Dago Rodriguez Email & Phone Number

California, United States

Madison, Wisconsin, US

Madison, Wisconsin, US

Madison, Wisconsin, US

San Diego, California, US

i. Genomic lead for the strategic development of a portfolio of breast cancer liquid biopsy products utilizing circulating tumor cell & cfDNA-based liquid biopsy tests. Responsible for scientific diligence, evidentiary build planning and execution to demonstrate biomarker clinical utility. ii. The intellectual author responsible for the analytical.

i. Team leader responsible for providing technical expertise and scientific input to complete key project milestones for internal teams, Biopharma clients, and academic KOL.ii. Co-lead the design, execution, data analysis and scientific publication of a retrospective clinical study (257 individual CTC sequenced from 47 patients), showing that high genomic.

i. Built and established from its inception, the Epic Sciences Single CTC Isolation System, enabling the genomic characterization of single CTCs.ii. Lead efforts in the protocol and workflow optimization of our single-cell CNV assay (e.g. single-cell lysis, optimization in whole genome amplification and NGS library prep methods), resulting in the.

Developed a platform for single-cell genomic analysis based on low pass whole genome sequencing, to infer genome-wide copy number variations (CNVs) in single circulating tumor cells (CTCs) as well as in cfDNA isolated from the blood of cancer patients. The method proved effective to delineate and characterize patient’s tumor genomic heterogeneity and.

La Jolla, California, US

Genomics analysis, protein molecular dynamics and site directed mutagenesis were integrated to deduce and generated a molecular model of the autophosphorylation and transient active state of KinA bacterial Sensor Histidine kinsase. Publications1) Steiner E, Dago AE, Young D, Heap JT, Minton NP, Hoch JA and Young M. 2011. Multiple orphan histidine kinase.

Involved in the comprehensive characterization and mapping of transcriptional start sites (TSS) from all the genes expressed in the Escherichia coli K-12 genome. The method used to accomplish this goal was based on the pyrosequencing-454 of cDNA amplified libraries obtained under different growth conditions

Goal: To gain molecular insights into the mechanism of transcriptional activation of the genes controlled by the bacterial sigma 54-RNA polymerase.Publications1) Dago AE, Wigneshweraraj SR, Buck M and Morett E (2007). A role for the conserved GAFTGA motif of AAA+ transcription activators in sensing promoter DNA conformation. J Biol Chem.2) Bordes P.

Identification and characterization of the molecular determinants that mediated the interaction between the transcriptional activator and its cognate sigma 54 transcriptional factor (Esigma54) required for the formation of an open promoter complex.PublicationChaney M, Grande R, Wigneshweraraj SR, Cannon W, Casaz P, Gallegos MT, Schumacher J, jones S, Dago.

I designed, developed and implemented a DNA plasmid based on the replicate machinery of theSemliki Forest virus encoding the GP120 HIV protein aimed for DNA immunization.

Phd, Biochemistry

Master Degree, Biochemistry